INVESTIGATING THE PHYSIOLOGICAL RELATIONSHIP BETWEEN ISCHEMIC HEART DISEASE AND HYPOTHYROIDISM
MOHAMMED S. HUSSEIN
Department of Gastroenterology and Endoscopy, Dr Samir Abbas Hospital, Jeddah, KSA and Department of Internal Medicine, Faculty of Medicine, Alazhar University Hospitals, Cairo, Egypt.
BAYAN MUJAHID M KABY
Tabuk University, Saudi Arabia.
HAJAR YOUSIF ALYOUSIF
University of Jordan, Jordan.
SALEM ALI AL MARRI
King Fahad Hospital Hofuf, Saudi Arabia.
AHMAD ABDULAZIEM S. ALIBRAHIM
Alhannah Primary Health Care, Saudi Arabia.
MALAK BASSAM ALRASHEED
King Fahad Hospital Hofuf, Saudi Arabia.
ABDULAZIZ MOHAMMAD ALAIBAN
Imam Mohammad Bin Saud, Riyadh, Saudi Arabia.
WADEEAH JAFAR ALMANASSIF
Joudah Primary Health Care, Saudi Arabia.
SHAHID ABDULLAH ALMAHDI
King Fahad Hospital Hofuf, Saudi Arabia.
YAZEED FAHAD ALGHULAYQAH
Al Imam Mohammad Bin Saud , Riyadh, Saudi Arabia.
MANAR ABDULWAHAB ALABDULSALAM
Maternity and Children Hospital in Dammam, Saudi Arabia.
ABDULLAH MOHAMMED ALASSIRI
Najran University, Saudi Arabia.
ABDULAZIZ ALI AL-THABET
Najran University, Saudi Arabia.
*Author to whom correspondence should be addressed.
Abstract
Both hypothyroidism and hyperthyroidism, which are thyroid conditions that are extremely prevalent throughout the world, predispose to CVD in general and CAD in particular. This is especially important for people who have hypothyroidism. Heart failure progression risk and the frequency of coronary events are both raised by overt and subclinical hypothyroidism. Thyroid hormone abnormalities are a common complication of heart disease, especially ischemic heart disease, and should be taken into consideration. In actuality, it is necessary to consider low thyroid hormone levels as a cardiovascular risk factor. Regarding ischemic heart disease, thyroid hormones impact left ventricular structure, function, and geometry in the late post-myocardial infarction stage. Cardio-protection is the new goal of therapies to reduce infarct size and stop the development of heart failure following an acute ischemic event in order to enhance cardiovascular outcomes. Through TR1 binding, TH replacement therapy administered soon after myocardial infarction (or even when delayed) may enhance cardiac function. In this review we will look at the relationship between hypothyroidism and ischemic heart disease.
Keywords: Heart disease, hypothyroidism, cardiac, blood pressure, hyperthyroidism, thyroid